JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003)[1].
Target:
CD3,Transmembrane Glycoprotein
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
